An open label study of clobetasol propionate 0.05% and betamethasone valerate 0.12% foams in the treatment of mild to moderate acne keloidalis.
Acne keloidalis (AK) is a disease affecting primarily African American men. Topical steroids are a widely accepted treatment of AK; however, no studies have been published investigating their effectiveness. The purpose of this open-label study was to assess the efficacy and tolerability of clobetasol propionate 0.05% and betamethasone valerate 0.12% foams in the treatment of AK in 20 African American patients. These patients were treated for 8 to 12 weeks using a pulsed-dose regimen. We found topical clobetasol propionate foam to be effective in improving AK, and our patients found the foam vehicle to be cosmetically acceptable.
Callender
Valerie D
VD
Callender Skin & Laser Center, 12164 Central Ave, Suite 225, Mitchellville, MD 20721, USA. drcallender@callenderskin.com
Young
Cherie M
CM
Haverstock
Christina L
CL
Carroll
Christie L
CL
Feldman
Steven R
SR
D000153:Acne Keloid / Q000188:drug therapy*; D000287:Administration, Topical; D000328:Adult; D001741:Black or African American; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001624:Betamethasone Valerate / Q000008:administration & dosage* / Q000009:adverse effects; D002990:Clobetasol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D012536:Scalp Dermatoses / Q000188:drug therapy*; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D001624:Betamethasone Valerate; D002990:Clobetasol